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Glycogen synthase kinase (GSK) 3 has been identi-
fied as a regulator of immune responses. We demon-
strated previously that GSK3 inhibition in human
brain microvascular endothelial cells (BMVECs) re-
duced monocyte adhesion/migration across BMVEC
monolayers. Herein, we tested the idea that GSK3
inhibition in monocytes can diminish their ability to
engage the brain endothelium and migrate across the
blood-brain barrier. Pretreatment of primary mono-
cytes with GSK3 inhibitors resulted in a decrease in
adhesion (60%) and migration (85%), with similar
results in U937 monocytic cells. Monocyte-BMVEC in-
teractions resulted in diminished barrier integrity
that was reversed by GSK3 suppression in mono-
cytic cells. Because integrins mediate monocyte roll-
ing/adhesion, we detected the active conformational
form of very late antigen 4 after stimulation with a
peptide mimicking monocyte engagement by vascu-
lar cell adhesion molecule-1. Peptide stimulation re-
sulted in a 14- to 20-fold up-regulation of the active
form of integrin in monocytes that was suppressed by
GSK3 inhibitors (40% to 60%). Because small
GTPases, such as Rac1, control leukocyte movement,
we measured active Rac1 after monocyte activation
with relevant stimuli. Stimulation enhanced the
level of active Rac1 that was diminished by GSK3
inhibitors. Monocytes treated with GSK3 inhibitors
showed increased levels of inhibitory sites of the actin-
binding protein, cofilin, and vasodilator-stimulated
phosphoprotein-regulating conformational changes of
integrins. These results indicate that GSK3 inhibi-
tion in monocytes affects active integrin expression,
1414cytoskeleton rearrangement, and adhesion via sup-
pression of Rac1-diminishing inflammatory leuko-
cyte responses. (Am J Pathol 2012, 181:1414–1425; http://
dx.doi.org/10.1016/j.ajpath.2012.06.018)
Leukocyte interactions with the endothelium are at the cen-
ter of inflammatory responses. Such interactions are highly
orchestrated, leading to the sequential steps of tethering,
rolling, arrest, firm adhesion, and migration across the en-
dothelium.1 Integrins [lymphocyte function-associated anti-
gen 1 or L2 integrin, macrophage receptor 1, known as
integrin M2, and very late antigen 4 (VLA-4), also known
as integrin 41] expressed on the surface of leukocytes
are primarily responsible for arrest and firm adhesion, and
they mediate leukocyte tethering and rolling.2 The level of
expression and, more recently, multifaceted conformational
changes of integrins have emerged as key factors in the
pro-inflammatory phenotype of leukocytes transitioning
from the resting to the activated state, with enhanced ad-
hesion potential.3 However, the mechanism regulating
these changes remains elusive.4
Integrins can be quickly transformed to the active state
by so-called inside-out signaling after stimulation of G-
coupled receptors by chemokines or other inflammatory
factors via intracellular signaling, leading to binding of
talin to intracellular integrin domains.4 Such alterations
result in conformational unbending and increased affinity
of integrins. The development of antibodies to detect
expression of active integrin conformation has allowed a
better understanding of the interactions of leukocytes with
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tects the active conformational state of VLA-4 integrin that
interacts with vascular cell adhesion molecule (VCAM)-1.
Cross-linking with antibodies to integrin (eg, integrin 4,
also known as CD49d) or stimulation with L-leucyl-L-aspar-
tyl-L-valyl-L-prolyl-L-alanyl-L-alanyl-L-lysine (LDV) peptide
mimics leukocyte endothelial interaction without actual en-
dothelial cell engagement. LDV peptide is a peptide con-
sensus sequence of VCAM-1 and fibronectin, shown by
Chigaev et al3 to activate integrin 1 conformational
change. We used LDV peptides as a specific inducer for
the active VLA-4 conformation and subsequently used the
conformation-specific HUTS21 antibody to detect the
change in VLA-4, to analyze the effects of glycogen syn-
thase kinase (GSK) 3 inhibition on the processes regulat-
ing monocyte adhesion and migration.
GSK3 is a serine-threonine protein kinase that is con-
stitutively active in cells, and numerous factors exert their
effects by inhibiting GSK3 activity.5 GSK3 activity is
inhibited by phosphorylation of a specific serine residue
(S9) located in the GSK3 N-terminal domain. Down-
stream targets of GSK3 include transcription factors (-
catenin, cAMP response element binding protein, and c-
Jun), proteins bound to microtubules (), cell cycle
mediators, and regulators of metabolism.6 The anti-inflam-
matory effects of GSK3 inhibition have been recognized
and include a decrease in cytokine-chemokine secretion
and expression of adhesion molecules.7 Diminished leu-
kocyte migration after GSK3 suppression has been
shown in vitro and in animal models for Gram-negative
shock and multiorgan injury,8–11 multiple sclerosis,12
stroke,5 and spinal cord injury.7 Our published work in-
dicated potent anti-inflammatory effects of GSK3 inhibi-
tion in brain endothelium in vitro and in vivo.13 Yet, limited
information exists about direct anti-inflammatory effects
of GSK3 suppression in leukocytes.
Herein, we demonstrate, for the first time to our knowl-
edge, that GSK3 inhibition in monocytes diminishes the
expression of active VLA-4 and attenuates monocyte ad-
hesion to and migration across brain microvascular en-
dothelial cell (BMVEC) monolayers. We also show that
GSK3 inhibition suppresses the activity of the small
GTPase, Rac1; diminishes lamellipodia formation; and in-
creases expression of phosphorylated forms of cofilin (an
actin-binding protein that is involved in leukocyte migration)
and vasodilator-stimulated phosphoprotein (VASP; control-
ling up-regulation of active VLA-4). These previously unrec-
ognized effects of GSK3 in monocytes, coupled with our
observations in BMVECs,13 indicate that GSK3 inhibition
could be an attractive target for treatment of inflammation
and blood-brain barrier (BBB) injury.
Materials and Methods
Reagents and Cells
Recombinant human tumor necrosis factor (TNF)- and
monocyte chemoattractant protein 1/chemokine ligand
(CCL)2 were obtained from R&D Systems (Minneapolis,
MN). GSK3 inhibitors were obtained as follows: lithiumchloride (LiCl; Sigma/Aldrich Co, Ltd, St Louis, MO),
5-iodo-indirubin-3=-monoxime (I3=M; EMD Chemicals,
San Diego, CA), N-(4-methoxybenzyl)-N=-(5-nitro-1,3-
thiazol-2-yl) urea [AR-A014418 (AR); Sigma/Aldrich Co,
Ltd], and 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-
yl)-1H-pyrrole-2,5-dione [SB 216763 (SB2); Cayman
Chemical Co; Ann Arbor, MI]. Rac1 GTPase-specific in-
hibitor, NSC23766 (NSC), was obtained from EMD Chem-
icals. Concentrations of inhibitors were based on previ-
ously published work14 and our initial dose-response
experiments with different exposure times. Lysophospha-
tidic acid (LPA) and lipopolysaccharide (LPS) were ob-
tained from Sigma/Aldrich Co, Ltd, and Cayman Chemi-
cal Co, respectively.
Primary BMVECs were supplied by Dr. Michael Bernas
and Dr. Marlys Witte (University of Arizona, Tucson).
BMVECs were isolated from the vessels from the brain
resection path of patients (showing no abnormalities)
undergoing surgery for the treatment of intractable ep-
ilepsy, as previously described.15–17 BMVEC cultures
were used until passage 5 and were expanded in Dul-
becco’s modified Eagle’s medium/F-12 media supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS; Invitrogen/Life Technologies, Carlsbad, CA), endo-
thelial cell growth supplement (BD Bioscience, Franklin
Lakes, NJ), heparin (1 mg/mL; Sigma/Aldrich Co, Ltd),
amphotericin B (2.5 g/mL; Invitrogen/Life Technolo-
gies), penicillin (100 U/mL; Invitrogen/Life Technologies),
and streptomycin (100 g/mL; Invitrogen/Life Technolo-
gies). Before experimentation, BMVEC monolayers were
placed in media containing the previously described
supplements but lacking endothelial cell growth supple-
ment and heparin. Under these conditions, the BMVEC
cultures were routinely evaluated for expression of endo-
thelial cell markers (von Willebrand factor and CD31/
platelet endothelial cell adhesion molecule-1) and tight
junction proteins (zonula occludens protein 1, occludin,
and claudin-5) and the lack of macrophage (CD68 and
CD163), astrocyte (glial fibrillary acidic protein), and peri-
cyte (-myosin) markers. BMVEC purity was usually ap-
proximately 97%.15,18,19
Primary human monocytes were supplied by the Hu-
man Immunology Core of the University of Pennsylvania,
Philadelphia. Flow cytometry analysis was used to con-
firm that the cells were 90% CD14 positive.20 The cells
were isolated by countercurrent centrifugal elutriation
and maintained in suspension culture in Dulbecco’s mod-
ified Eagle’s medium containing heat-inactivated 10%
FBS, penicillin (100 U/mL), streptomycin (100 g/mL),
and L-glutamine (2 mmol/L)15,21 and were used within 24
hours of isolation.
The human myeloid leukemia cell line, U937 (obtained
from ATCC, Manassas, VA), was grown in RPMI 1640
medium containing 10% heat-inactivated FBS supple-
mented with 100 U/mL penicillin, 100 g/mL streptomy-
cin, and 2 mmol/L L-glutamine.
Primary monocytes and U937 cells were maintained in
5-mL polystyrene round-bottom tubes in suspension
(Becton Dickinson, Franklin Lakes, NJ) before use and
detached by shaking the tube. Both primary monocytes
and U937 cells were pretreated with inhibitors overnight
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cause any toxic effects on viability of the cells, as deter-
mined using the Live/Dead Cell Viability Assay (Invitro-
gen/Life Technologies) (see Supplemental Figure S1B at
http://ajp.amjpathol.org).
Adhesion and Migration Assays
Quantitative adhesion assays were performed as previ-
ously described.18 In brief, BMVECs were seeded on
collagen type I–coated 96-well plates at a density of
2.5  104 cells per well. Confluent monolayers were then
exposed to TNF- (20 ng/mL) for 24 hours to activate the
BMVECs. U937 cells or freshly isolated human mono-
cytes at 5  106 cells/mL were pretreated with GSK3
inhibitors and then labeled with 5 mol/L fluorescent
tracer, calcein-AM (Invitrogen/Life Technologies). Pre-
treatment by GSK3 inhibitors did not have any effect on
calcein-AM staining, as assessed by fluorescence-acti-
vated cell sorting (FACS; see Supplemental Figure S1A at
http://ajp.amjpathol.org). All treatments were removed
from the endothelial cells, and from monocytes, before
adding monocytes at 2.5 105 cells per well. Monocytes
were added to BMVECs, incubated for 15 minutes, and
then rinsed three times with one times PBS to eliminate
nonadherent monocytes. The fluorescence from adher-
ent or migrated monocytes was measured using a Spec-
tramax M5 fluorescence plate reader (Molecular Devices,
Sunnyvale, CA). The number of migrated monocytes was
determined from external standards of known numbers of
labeled monocytes. The results for adhesion assays are
presented as the mean  SEM fold adhesion (number of
adherent monocytes for each experimental condition/
basal adhesion of the untreated control).
The transendothelial migration assay was performed
as previously described.13 FluoroBlok (BD Bioscience,
Bedford, MA) cell culture inserts, designed to block the
transmission of fluorescent light between 490 and 700
nm, were used to allow for continuous detection of fluo-
rescently labeled monocytes migrating across endothe-
lial monolayers. BMVECs were seeded on collagen type
I–coated pore (3 m thick) 24-well tissue culture Fluo-
roBlok inserts at a density of 2.5  104 cells per insert.
Confluent monolayers were then exposed to TNF- (20
ng/mL) for 24 hours to activate the BMVECs. After acti-
vation, BMVECs were rinsed with fresh medium, and the
medium was replaced. U937 or primary monocytes were
pretreated with or without GSK3 inhibitors overnight and
rinsed with fresh medium, and the medium was replaced,
before calcein-AM labeling. For migration assays, cal-
cein-AM–labeled monocytes were added to the upper
chamber of the tissue culture insert system, whereas the
chemoattractant, CCL2/monocyte chemoattractant pro-
tein 1 (50 ng/mL), was added to the lower chamber to
stimulate migration. The cells were then incubated for 2
hours at 37°C in a tissue culture incubator. The fluores-
cence from migrated monocytes was measured using a
Spectramax M5 fluorescence plate reader (Molecular De-
vices). The number of migrated monocytes was determined
from external standards of known numbers of labeled
monocytes. The results for migration assays are shown asthe average fold migration  SEM; the fold migration is
derived from the number of migrated monocytes for each
experimental condition/number of migrated monocytes in
the untreated, no chemoattractant control.
TEER Data
To determine the integrity of brain endothelial monolayers
after engagement with monocytes, transendothelial elec-
trical resistance (TEER) was measured using the 1600R
Electric Cell-substrate Impedance Sensing (ECIS) sys-
tem (Applied Biophysics, Troy, NY). By using the free
ions in the culture media, the instrument generates an
a.c. flow between the electrode and counterelectrode
located in specialized tissue culture arrays and measures
the change in impedance. The ECIS system provides
real-time complex impedance, providing readouts for im-
pedance, resistance, and capacitance. In brief, BMVECs
were plated on collagen type I–coated electrode arrays
(96W10E; Applied Biophysics). The cells were then al-
lowed to form monolayers, reaching stable TEER values.
After achieving basal TEER readings because of mono-
layer and tight junction formation, the BMVECs were in-
cubated overnight in the absence or presence of TNF-
(20 ng/mL). Medium was replaced on the BMVECs, and
monocytes (untreated or pretreated with GSK3 inhibi-
tors) were added at 5  104 cells per well (10:1 ratio of
monocytes/BMVECs). All treatments were removed from
the BMVECs, and monocytes were washed before add-
ing them to the wells. Measurements were taken every 30
minutes at 4000 Hz. The average baseline TEER readings
varied between 800 and 1500 /cm2. The results are
presented as the average  SEM percentage change of
baseline TEER from at least three independent experi-
ments consisting of at least two replicates.
VLA-4 Ligation and Cross-Linking
For integrin engagement studies, U937 cells were sus-
pended in RPMI 1640 medium/1% FBS/L-glutamine at 5 
106 cells/mL. Surface CD49d antigen was ligated with
monoclonal antibody (HP2/1; Beckman Coulter Inc., Brea,
CA) at 4°C for 25minutes at 15g/mL, washed twice in cold
RPMI 1640 medium, and then cross-linked with 5 g/mL
goat anti-mouse F(ab’)2 (Thermo Scientific, Rockford, IL) for
25 minutes at 4°C. This concentration of primary antibody
was saturating by flow cytometry.22 Cells were washed
twice in cold RPMI 1640 medium, resuspended in RPMI
1640 medium/1% fetal calf serum/L-glutamine, and incu-
bated at 37°C and 5%CO2 for times ranging from 0minutes
to 1 hour. Reactions were stopped by placing the cells on
ice. In inhibition studies, U937 cells were pre-incubated in
the presence of GSK3 inhibitors overnight.
Rac1 Guanosine Triphosphatase (GTPase)
Activity Assay
Rac1 GTPase activity was measured in cell lysates pre-
pared from unstimulated (basal) or stimulated primary
monocytes or U937 cells (with or without pretreatment
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with antibody or alternatively stimulated with LPS (100 ng/
mL) or LPA (100 ng/mL), known activators of GTPases,
which served as positive controls.23 To measure Rac1
GTPase activity, a commercially available G-LISA Rac1 Ac-
tivation Assay kit (Cytoskeleton Inc., Denver, CO) was used,
according to manufacturer instructions.
Western Blot Analysis
After integrin cross-linking, U937 cells were lysed in ice-
cold cell lysis buffer containing 1% Triton X-100, 150
mmol/L NaCl, 10 mmol/L Tris-HCl (pH 7.4), 2 mmol/L so-
dium orthovanadate, 10g/mL leupeptin, 50mmol/L NaF, 5
mmol/L EDTA, 1 mmol/L EGTA, and 1 mmol/L phenylmeth-
ylsulfonyl fluoride. Supernatants were collected after centrif-
ugation at 10,000  g for 5 minutes at 4°C. The protein
content in the cell lysates was determined using the Brad-
ford protein assay (BioRad, Hercules, CA). Protein frac-
tions containing 20 g of protein were mixed with two
times Laemmli (sample loading) buffer containing -mer-
captoethanol and then boiled for 5 minutes. The proteins
were then resolved by SDS-PAGE (4% to 20% precast
gels; Thermo Scientific), followed by electrophoretic trans-
fer to nitrocellulose membranes. The following primary an-
tibodies, diluted in one times PBS/0.1% Tween 20, were
used to detect target proteins: anti-phosphorylated-cofilin
and anti-phosphorylated-VASP (Cell Signaling Technology,
Beverly, MS), anti-cofilin, anti-VASP, anti-Grb-2 protein, and
loading control (Santa Cruz Biotechnology, Santa Cruz,
CA). All antibodies were incubated with the membranes
overnight at 4°C with gentle shaking. Bound primary anti-
bodies were exposed to the corresponding species-spe-
cific fluorescent IRDye680 or IRDye800 infrared secondary
antibodies (diluted 1:20,000; LI-COR, Lincoln, NE) for 30
minutes at room temperature, and detected using the LI-
COR Odyssey imaging system.
Conformational Changes of VLA-4
VLA-4–activated conformation, detected by HUTS21
binding, was studied by FACS, as previously described.3
Studies by Chigaev et al24–26 indicated that binding of
the VLA-4–specific ligand, LDV, to integrin induces a
series of conformational changes resulting in the expo-
sure of the HUTS21 epitope. In our experiments, we used
LDV as a specific stimulator of active VLA-4 conformation.
LDV was synthesized by Invitrogen/Life Technologies.
FACS analysis was performed using mouse anti-human in-
tegrin 1 (CD29) clone HUTS21 (phosphatidylethano-
lamine), mouse anti-human CD29 clone MAR4 (activated
protein C), phosphatidylethanolamine, and activated pro-
tein C isotype control (mouse IgG2a ) clone G155 to G178.
Cells (106 cells/mL) removed from ice were warmed in
HEPES buffer containing 0.1% bovine serum albumin for
10 minutes at 37°C. First, samples were analyzed for 30
to 120 seconds to establish a baseline for unstained
cells. Next, the tube was removed, HUTS21 antibody
(Ab) was added (20 L of Ab to 1 mL of cell suspension),
and acquisition was re-established. To induce VLA-4
conformational change, 12 nmol/L LDV (saturating con-centration3) was added and mixed. Acquisition was re-
established, and data were acquired, collecting 10,000
events. Analysis was performed using an FACS BD Cali-
bur flow cytometer (BD Biosciences, San Jose, CA) using
Cell Quest software (BD Biosciences) or FlowJo software
(Tree Star, Inc., Ashland, OR). Quantitation of integrin 1
conformational activation was performed, in which the
mean fluorescence intensity (MFI) of activated non-
treated cells was assigned a value of 100, and a value of
0 was assigned to the MFI of cell autofluorescence. All
other calculations were performed using the regression
curve calculation tool of Prism version 5 software
(GraphPad Software Inc., La Jolla, CA).
Visualization of Lamellipodia
For immunofluorescence studies, cells were fixed with
4% formaldehyde in PBS for 15 minutes on ice. Cells
were permeabilized with 0.1% Triton X-100 in PBS for 10
minutes. For localization of F-actin filaments, cells were
incubated with 14 mol/L Acti-stain 488 fluorescent phal-
loidin (Cytoskeleton Inc.) for 45 minutes at room temper-
ature and DAPI (300 nmol/L) for 20 minutes at room
temperature. Images of 20 cells per treatment were taken
at 63 (1024  1024 pixel area) using a Leica Sp5
confocal laser-scanning microscope (Leica Microsys-
tems GmbH, Mannheim, Germany) using Leica LAS AF
software, and were processed with Adobe Photoshop
CS3 software (Adobe Systems Inc., San Jose, CA). The
area (in pixels) of each lamellipodium per cell was mea-
sured using ImageJ software (NIH, Bethesda, MD), and
the average lamellipodium area per cell in each captured
image was used for statistical analysis.
Human Brain Tissue
To investigate expression of total and active forms of
phosphorylated GSK3 in neuroinflammation, we used
seven cases (frontal cortex) of HIV-1 encephalitis (HIVE)
and four seronegative age-matched controls provided by
the National NeuroAIDS Consortium (Washington, DC),
previously described.13 The Institutional Review Board
approved these studies. Serial paraffin sections (5 m
thick) were cut and double immunostained (by indirect
immunofluorescence) for CD68 (monoclonal Abs; dilu-
tion, 1:200; DakoCytomation, Carpentaria, CA), and the
GSK3 active form was phosphorylated on T216 (poly-
clonal Abs; dilution, 1:50; Abcam, Cambridge, MA). The
infiltration of activated macrophages and the level of in-
fection were assessed using monoclonal Abs to HLA-DR
(dilution, 1:200; DakoCytomation) and HIV-1 p24 (dilu-
tion, 1:10; DakoCytomation) on paraffin serial sections
with the avidin-biotin immunoperoxidase Vectastain Elite
ABC kit (Vector Laboratories, Burlingame, CA).27
Statistical Analysis
The values shown in all figures and those mentioned in
the text represent the average SEM of experiments that
were conducted multiple times (as indicated). Multiple
group comparisons were performed by one-way anal-
, lumen;
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assay, migration assay, FACS, and G-LISA). Statistical
analyses were performed using Prism version 5 soft-
ware (GraphPad Software Inc.). Differences were con-
sidered significant at P  0.05.
Results
Active Form of GSK3 Is Expressed in
Infiltrating Monocytes and Macrophages in HIVE
Our previous work suggested that GSK3 was activated
in brain endothelium in HIVE.13 Herein, we investigated
whether activated GSK3 was up-regulated in mononu-
clear phagocytes within human brain tissues during neu-
roinflammation (eg, HIVE). Although control brain tissues
showed minimal staining for HLA-DR (a macrophage ac-
tivation marker) and no staining for HIV-1 p24 (Figure 1, A
and B), HIVE cases demonstrated numerous HLA-DR–
and p24-positive perivascular macrophages (Figure 1, D
and E). Next, we used phospho-specific antibodies to
T216 (on GSK3), which is located on the activation loop
of GSK3, indicating an increase in GSK3 catalytic ac-
tivity28 detecting the active form of GSK3 (p-GSK3,
phosphorylated at T216) and CD68 (a monocyte/macro-
phage marker). Control brains demonstrated minimal to
no staining with antibodies to p-GSK3 in perivascular
macrophages (Figure 1C). A high level of p-GSK3 was
detected in perivascular CD68-positive mononuclear
cells (Figure 1F), macrophages, and microglia within mi-
croglial nodules in brain tissues of patients with HIVE
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Figure 1. Active forms of GSK3 are detected in mononuclear phagocytes in
(D–F) are cut. The sections are immunostained with anti-HLA-DR (A and D)
CD68/DAPI (red/blue; C and F). There is no staining for HLA or p24 in con
(E) perivascular monocytes/macrophages (arrowheads). Similarly, minimal
monocytes/macrophages (arrowheads) show a high level of p-GSK3 (F). L
(C and F).(data not shown). Total GSK3 showed similar expres-sion in control and HIVE brain tissues (data not shown).
These results indicated that GSK3 was activated in
mononuclear phagocytes, in addition to brain endothe-
lium, during neuroinflammation (eg, HIVE).
GSK3 Inhibition in Monocytes Attenuate Their
Adhesion to Brain Endothelium and
Transendothelial Migration
Previous studies from our laboratory showed protection
of BBB integrity by GSK3 inhibition in BMVECs associ-
ated with diminished monocyte adhesion to endothelial
cells and migration across BBB models.13 We also ob-
served substantial diminution in leukocyte adhesion to
brain endothelium in vivo using intravital microscopy. Be-
cause both endothelium and leukocytes could be the
subject of GSK3 inhibition in vivo, in the present study,
we investigated whether suppression of GSK in mono-
cytes would also result in decreased inflammatory re-
sponses. We pretreated monocytic cells, U937, or pri-
mary human monocytes with GSK3 inhibitors to study
their effects on monocyte adhesion to brain endothelium.
Adhesion assays revealed that exposure of BMVEC to
TNF- induced an increase in adhesion of U937 mono-
cytic cells (Figure 2A) and primary monocytes (Figure
2C), fourfold and sevenfold, respectively. Pretreatment of
U937 monocytic cells with GSK3 inhibitors (Figure 2A)
led up to a 60% dose-dependent reduction (P  0.01) in
adhesion (with the highest doses of LiCl, I3=M, and SB2)
compared with adhesion of untreated cells to TNF-–
activated BMVECs. Pretreatment of U937 cells with the
CD68
DAPI
p-GSK
L
P.S.
CD68
DAPI
p-GSKC
F
Paraffin sections (5 m thick) of control human brains (A–C) or HIVE brains
(B and E) or double immunostained with p-GSK3 Ab (green; C and F) and
tissues (A and B). HIVE cases demonstrate HLA-DR– (D) and p24-positive
for p-GSK3 is found in CD68-positive macrophages (C). In HIVE, infiltrating
P.S., perivascular space. Original magnification:200 (A, B, D, and E);40024
P.S.
HIVE.
or p24
trol brain
stainingRac1-specific inhibitor, NSC,29 had a similar effect on
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duction of approximately 40%). A decline in adhesion
could also result in a decrease in the number of mono-
cytes crossing the BBB. By using migration assays in an
in vitro BBB model, we tested whether GSK3 inhibition in
monocytes could prevent monocyte passage across BM-
VEC monolayers. We used CCL2 as a relevant cytokine
that is up-regulated in the brain under neuroinflammatory
conditions. The addition of CCL2 to the lower chamber of
the BBB model resulted in a 2.5-fold enhanced migration of
U937 cells (Figure 2B) and a fivefold increase in migration
of primary human monocytes (Figure 2D) compared with
control constructs without chemokine addition. Treatment of
monocytes with the GSK3 inhibitors, LiCl, I3=M, or SB2, led
to attenuation in the migration of U937 monocytic cells by
85%  8%. Exposure of primary monocytes to GSK3
inhibitors prevented their ability to cross the BBB by 93%
3%. These results suggested that GSK3 inhibition in
monocytes reduced both adhesion and migration across
activated endothelial monolayers. Pretreatment of primary
monocytes with GSK3 inhibitors (Figure 2C) resulted in
approximately 26% to 53% reduction of monocyte attach-
ment compared with adhesion of untreated monocytes to
TNF-–treated BMVECs.
GSK3 Inhibition in Monocytes Diminishes BBB
Injury
One of the early stages of neuroinflammation was the
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Figure 2. GSK3 inhibitors reduce monocyte adhesion to and migration across
BMVEC monolayers. A and C: BMVECs are stimulated with TNF- (20 ng/mL,
overnight) or left untreated. Calcein-labeled U937 cells (pretreated with different
concentrations of LiCl, I3=M, SB2, or NSC for 24 hours) (A) or primary human
monocytes (pretreated with 20 mmol/L LiCl or 1 mol/L I3=M) (C) are washed
with PBS, added to BMVECs, and allowed to adhere for 15 minutes. Unattached
cells are rinsed with PBS, and the fluorescence is measured. The number of
adherent cells is calculated based on a standard curve derived from the fluores-
cence intensity of known amounts of labeled cells. B and D: Transendothelial
migration of U937 cells (B) or monocytes (D) is performed across TNF-–
stimulated BMVEC monolayers using CCL2 (50 ng/mL) as the chemotactic stim-
ulus. Calcein-labeled U937 cells (B) or monocytes (D) pretreated with GSK3
inhibitors (20 mmol/L LiCl, 1 mol/L I3=M, or 5 mol/L SB2) are added to
BMVEC monolayers, and the monocytes are allowed to migrate for 2 hours.
Fluorescence is measured as described inMaterials andMethods. Data represent
the mean  SEM values of fold difference from three different experiments
performed in triplicate; primary monocytes are from two different donors. *P 
0.01, †P  0.05 indicates significant inhibition.adhesion and engagement of leukocytes with microvas-cular endothelial cells. Engagement by leukocytes and
subsequent migration across the BBB led to enhanced
barrier permeability. We hypothesized that, because
GSK3 inhibition in monocytes reduced their ability to
attach and migrate through BMVEC monolayers (Figure
2), it would also prevent monocyte-mediated disruption of
the BBB. To evaluate this idea, we treated U937 cells with
GSK3 inhibitors before their addition to BMVEC mono-
layers plated on ECIS electrode arrays, with or without
TNF- exposure. The integrity of the barrier was evalu-
ated by measuring TEER (Figure 3). The addition of un-
treated monocytes to BMVECs resulted in a 9.5% 0.5%
decrease of TEER during the first 9 hours, whereas the
addition of GSK3 inhibitor-treated monocytes produced
a 4% decrease in TEER. Stimulation of BMVECs by
TNF-, without addition of monocytes, did not produce a
significant effect on transendothelial electrical resistance.
Figure 3 shows that, in wells in which GSK3 inhibitor-
treated monocytes were added to BMVECs, tightness of
the barrier recovered to initial levels after 21 hours,
whereas tightness of BMVEC monolayers with untreated
monocytes was reduced by approximately 12%, even at
21 hours. The addition of untreated or treated U937 cells
to BMVECs had similar effects on TEER (data not shown).
Thus, GSK3 inhibition in monocytes protected against
the leakiness of the BBB because of diminished immune
cell engagement with the brain endothelium.
Integrin Activation Affected by GSK3 Inhibition
Because GSK3 inhibition in monocytes affected their
ability to attach to and migrate across endothelial mono-
layers, we hypothesized that the activation status of in-
tegrin (ensuring rolling and firm adhesion of leukocytes)
would be affected in monocytes after GSK3 inhibition.
To study active integrins, we used conformationally sen-
sitive monoclonal Abs binding to epitopes usually hidden
in resting cells and exposed only in the active conforma-
tion. Chigaev et al3 showed rapid conformational
changes in VLA-4 using the conformationally sensitive
monoclonal Ab, HUTS21, after stimulation with a VLA-4
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Figure 3. GSK3 inhibition in monocytes improves barrier function. TEER is
measured in BMVECs with TNF- pretreatment during engagement by
monocytes. Results from a representative experiment with the GSK3 inhib-
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AJP October 2012, Vol. 181, No. 4ligand (LDV peptide), an inducer of conformational
change. By using the same approach, we analyzed
HUTS21 binding in U937 cells (Figure 4). The addition of
HUTS21 antibody to U937 cells resulted in 4% to 5%
binding in non–LDV-stimulated samples (Figure 4A). Ex-
posure to LDV peptide shifted integrin 1 conformation
toward the activated, open form (Figure 4A). To test if
GSK3 inhibition of monocytes could affect activation of
VLA-4, we treated U937 cells with GSK3 inhibitors (LiCl,
I3=M, or AR) (Figure 4A). HUTS21 binding to activated
integrin  was quantified by FACS before and after LDV
stimulation in inhibitor-treated cells. LDV exposure in-
creased the change to the active VLA-4 configuration by
20-fold, and GSK3 inhibition decreased activation of
integrin 1 by 60%  6% (Figure 4B). Because Rac1
GTPase was involved in activation of VLA-4 integrins,30,31
we treated U937 cells with the Rac1-specific inhibitor,
NSC. Pretreatment of U937 cells with NSC showed a
similar diminution in active integrin expression, as in
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Figure 4. GSK3 inhibition prevents conformational activation of VLA-4 in
U937 cells. A: Stimulation of U937 cells with LDV (a peptide consensus
sequence of VCAM-1 and fibronectin3) leads to changes in integrin 1
conformation from a closed (not active, gray) to an open (active, black) form.
U937 cells treated with LiCl, I3=M, AR, or NSC active form of VLA-4 (green).
The expression of total VLA-4 is not affected by inhibitors (A, right panel).
B: Quantitation of integrin 1 conformational activation in which the MFI of
activated nontreated cells is assigned a value of 100. The results are shown
as the mean  SEM from three independent experiments. *P  0.05 versus
untreated control. Max, maximum.GSK3 inhibitor-treated cells.Next, we measured activation of integrin 1 in primary
monocytes using the same approach (Figure 5). In pri-
mary monocytes, LDV enhanced expression of active
VLA by 14-fold. The Rac1 inhibitor, NSC, attenuated in-
tegrin activation by 40%  2%. LiCl, I3=M, and AR treat-
ment resulted in 40%, 45%, and 30% diminution in active
VLA-4 conformation, respectively. Total levels of integrin
1 were not affected by any treatment in either U937 cells
(Figure 4) or primary monocytes (Figure 5). In summary,
GSK3 or Rac1 inhibition suppressed the conformational
activation of VLA-4.
Rac1 Activation Is Reduced in Monocytes by
GSK3 Inhibition
To detect the active, GTP-bound form of Rac1, we used
a commercially available G-LISA kit (Cytoskeleton Inc.).
Activation of integrin signaling can be achieved by cross-
linking with antibodies mimicking engagement with en-
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Figure 5. GSK3 inhibition prevents conformational activation of VLA-4
(integrin 1) in primary human monocytes. Stimulation with LDV results in
expression of active VLA-4 (integrin 1) detected by HUTS21 monoclonal
Ab. A: Pretreatment of primary monocytes with LiCl, I3=M, AR, or NSC
significantly down-regulates the active form of VLA-4 (green). GSK3 inhib-
itors did not affect total expression of VLA-4 (integrin 1) (right column). B:
Quantitation of integrin 1 conformational activation in human monocytes in
which the MFI of activated nontreated cells is assigned a value of 100. The
results are shown as the mean  SEM from three independent experiments.
*P  0.05 versus untreated control. Max, maximum.
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AJP October 2012, Vol. 181, No. 4dothelium.22,32 Cross-linking of the 4 subunit of VLA-4
induced Rac1 activation 2- and 2.5-fold in U937 cells and
primary monocytes, respectively (Figure 6, A and C). The
use of nonimmune IgG (negative control) had no effect on
Rac1 activation. Treatment with the GSK3 inhibitors,
LiCl and SB2, resulted in 95% and 80% reduction in Rac1
activation, respectively (P  0.01), in U937 cells, and in
41% and 46% reduction in primary monocytes, respec-
tively. The addition of I3=M had less of an effect on Rac1
activation in U937 cells (approximately 50% reduction)
(P 0.05) and in primary monocytes (approximately 33%
reduction).
We next examined the ability of GSK3 inhibitors to
decrease Rac1 activation in primary monocytes stimu-
lated with LPA or LPS. A significant increase in Rac1
activation was observed in monocytes stimulated with
LPA or LPS (Figure 6, B and D), and a substantial inhibi-
tion (P  0.01) was observed in the presence of GSK3
inhibitors (LiCl, I3=M, and SB2), albeit at different levels.
Inhibitors did not have any effect on Rac1 baseline ac-
tivity in monocytes. In summary, for the first time to our
knowledge, we showed that GSK3 inhibition altered
Rac1 activation in monocytes.
GSK3 Inhibition Prevents Dephosphorylation
of Inhibitory Sites of VASP and Cofilin
To control and coordinate actin filament-based lamellipo-
dia formation and cell movement, efficient disassembly of
pre-existing actin filaments was necessary. A search for
proteins that regulate filamentous and globular actin lev-
els revealed an increase in the levels of an inactive phos-
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Figure 6. GSK3 inhibitors decrease Rac1 activation in primary monocytes.
Rac1 GTPase activity is measured in U937 cells (A and B) and primary
monocytes (C and D). A and C: Rac1 is activated in monocytes by cross-
linking of the VLA-4 receptor with -CD49d antibody (mimicking leukocyte
engagement with endothelial cells). Nonimmune IgG serves as the negative
control. Cells are starved (1% FBS/RPMI 1640 media supplemented with
penicillin-streptomycin for 24 hours) and then pretreated with inhibitors (20
mmol/L LiCl, 1 mol/L I3=M, or 5 mol/L SB2) overnight before cross-
linking. The level of Rac1 activity in non–cross-linked cells is assigned a
value of 1 to calculate the relative ratio of activation. B and D: Rac1 is
activated in monocytes by LPA (100 ng/mL, black bars) or LPS (100 ng/mL,
hatched bars) in the presence or absence of GSK3 inhibitors (20 mmol/L
LiCl, 1 mol/L I3=M, or 5 mol/L SB2). The level of Rac1 activity in non-
stimulated and nontreated cells is assigned a value of 1 to calculate the
relative ratio of activation. The results are shown as the mean  SEM value
from three independent experiments. *P  0.01, †P  0.05 versus untreated
control. neg, negative; NT, non-treated.phorylated form of the F-actin–severing protein, cofilin, incells unable to generate actin-based lamellipodia. Rac1
has been implicated in the dynamic regulation of cofilin
activity in several cell types.33 After detection of cofilin
phosphorylation in U937 cells without stimulation, we ex-
amined the dynamics of cofilin phosphorylation in cells
undergoing changes in actin cytoskeletal reorganization.
As a stimulus for actin cytoskeletal rearrangements, we
used cross-linking of integrins by antibodies, similar to
the cross-linking used in the Rac1 activation assays.
Cross-linking did not substantially affect cofilin; however,
treatment of U937 cells with the GSK3 inhibitors, LiCl
and I3=M, resulted in a 50%  6% increase of phosphor-
ylation levels of the inhibitory site, pS3, of cofilin.34 SB2
treatment produced a 95%  7% increase in pS3-cofilin
(Figure 7). The effect of the Rac1-specific inhibitor, NSC,
on the phosphorylation level of pS3-cofilin was similar to
that of LiCl and I3=M.
Recently, the actin-binding protein, VASP, has been
shown to act in concert with Rac1.35–37 Because GSK3
inhibitors affect Rac1 activity, they could also implicate
phosphorylation of VASP protein in leukocytes. Because
S157 and S239 sites are conserved among mammals,38
we tested the levels of phosphorylation of these sites by
using Western blot analysis. Treatment of U937 cells with
LiCl or SB2 resulted in a significant (P  0.05) increase
(30%  7%) in phosphorylation of S157-VASP (Figure 7).
Application of the GSK3 inhibitor, I3=M, or the Rac1
inhibitor, NSC, had little effect on pS157-VASP levels.
Treatment of U937 cells with the inhibitors previously
described did not have any effect on phosphorylation of
pS239 (data not shown). Together, these results strongly
suggested that GSK3 inhibition affected actin-binding pro-
teins, cofilin and VASP, via Rac1 inhibition.
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Formation
Formation of lamellipodia was necessary for leukocyte
migration associated with recruitment of active Rac1 into
the leading edge of the cell.39 To assess the possibility
that inhibition of GSK3 affected lamellipodia formation,
the lamellipodia area of both U937 and primary mono-
cytes cells was measured. Maximum lamellipodia protru-
sion/formation was observed 30 minutes after addition of
LDV peptide or CN04, the G-switch direct activator of
small G protein (Cytoskeleton Inc.) (Figure 8A). The area
occupied by lamellipodia increased by 1.8- to 2-fold after
treatment with LDV or CN04. When primary monocytes or
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Figure 8. Effects of GSK3 inhibition on lamellipodia formation. Lamellipo-
dia areas are measured at the time of maximum protrusion after 30 minutes
of incubation of primary monocytes with LDV peptide. A: Images (taken at
63 objective) of primary monocytes stained with Acti-stain 488 fluorescent
phalloidin. Protruding lamellipodia are indicated (arrowheads). Primary
monocytes treated with or without GSK3 inhibitors (20 mmol/L LiCl, 1
mol/L I3=M, or 5 mol/L SB2), Rac1 inhibitor (75 mmol/L NSC), or GTPase
activator (1 g/mL CN04, positive control) are shown. The average lamelli-
podium area (in pixels) per cell (20 cells per treatment) is calculated for
primary monocytes (B) and U937 cells (C). The results are shown as the
mean  SEM value from two independent experiments. *P  0.01 compared
with untreated control.U937 cells were treated with GSK3 inhibitors (as de-
scribed for the previous experiments), the area of the
lamellipodia was reduced by 1.8- and 2.2-fold (P  0.01;
Figure 8, B and C). Inhibition of Rac1 by NSC also led to
a 1.7- and 2.4-fold decrease of lamellipodia formation in
primary monocytes and U937 cells, respectively, when
compared with nontreated LDV-stimulated control cells.
These data indicated that inhibition of GSK3 activity
reduced lamellipodia protrusion in monocytic cells via
Rac1 inhibition.
Discussion
Leukocyte-endothelial interactions are at the center of
any inflammatory response and ensuing subsequent tis-
sue injury. Monocyte infiltration across the BBB plays an
important role in neuroinflammatory conditions, such as
multiple sclerosis and HIVE.2 Diminution of monocyte
invasion is associated with lessened brain damage. In
the present study, we tested whether GSK3 inhibition
could attenuate monocyte adhesion and migration
across monolayers of primary human brain endothelial
cells. Enhanced adhesion of monocytes to TNF-–stimu-
lated BMVECs and their migration across BMVEC mono-
layers (driven by CCL2 chemotaxis) were decreased by
60% and 85%, respectively, after treatment of primary
monocytes or U937 cells with GSK3 inhibitors. Limited
data are available regarding the functional role of GSK3
and the Wnt pathway in leukocytes during inflammatory
processes. Inhibition of GSK3 by LiCl or activation of the
Wnt–-catenin pathway results in decreased monocyte
migration across endothelial monolayers.11 In vivo, inhibi-
tion of GSK3 dampened migration processes of mono-
cyte-derived dendritic cells induced by anthrax edema
toxin.40 However, the mechanisms leading to such
changes have not been addressed.
In migrating epithelial cells, GSK3 may function up-
stream of the Rho family of small dimeric G proteins
(GTPases, Rho, Rac, and Cdc42).41 The Rho GTPases
are regulatory molecules that link surface receptors to
organize the actin cytoskeleton, transendothelial leuko-
cyte migration, oxidative stress, and inflammation.42 In
leukocytes, Rac1 and Cdc42 regulate cell polarity, lamel-
lipodia formation, and direct migration, whereas RhoA
controls leukocyte tail retraction during transmigration.43
RhoA signaling is essential for integrin-dependent adhe-
sion to the endothelium via leukocyte function-associated
antigen (or L2) for intercellular adhesion molecule-1
and very late antigen (VLA-4; or 41) for VCAM-1.44 We
sought to determine whether Rac1 inhibition would me-
diate a decreased adhesion/migration of monocytes
across BMVEC monolayers. We measured the activation
of Rac1 by G-LISA after cross-linking with antibodies to
CD49d or by stimulation by LPA or LPS in both primary
monocytes and U937 monocytic cells. The significant
increase in active Rac1 after cross-linking or stimulation
was suppressed in both cell types by GSK3 inhibitors.
Little is known about the connection between GSK and
Rac1 in inflammatory cells. Inactivation of GSK3 in
monocytes from diabetic patients was associated with
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creased monocyte migration.45 Differences in cell culture
conditions and stimulus (platelet-activating factor) may
explain the observed differences. More important, sev-
eral reports have indicated suppression of immune cell
adhesion to13 and migration across12 the BBB in animal
models of systemic inflammation and experimental auto-
immune encephalomyelitis that could be, in part, medi-
ated by GSK3 inhibition in leukocytes.
Up-regulation of conformationally active VLA-4 was
linked to active Cdc42 and Rac1.46 Decreased migration
of monocytic cells correlated with diminished expression
of active VLA-4 (detected by HUTS21) on the cell surface
and a fourfold decrease in active Rac1 and Cdc42.46
Because we observed diminished adhesion of mono-
cytes treated with GSK3 inhibitors, we explored the idea
that suppression of GSK3 may result in conformational
changes of active integrin and/or total integrin expres-
sion. We used LDV consensus peptide stimulation to
reproduce activation of monocytes by VCAM-1 and fi-
bronectin during leukocyte adhesion.25 LDV stimulation
increased expression of conformationally active VLA–4
(14– to 20–fold) within minutes; GSK3 inhibitors or a
specific inhibitor of Rac1 decreased expression of active
VLA–4 by 40% to 60%. Expression of total VLA–4 was not
changed after LDV treatment, indicating that the confor-
mational status of VLA–4 is primarily responsible for the
adhesion observed in the presence of GSK3 inhibitors.
Previously, memory T cells that constitutively express
activation/ligand–induced epitopes on 1 integrins rec-
ognized by HUTS21 exhibited significantly higher rates of
attachment and accumulation on VCAM–1–expressing
cells compared with other T–cell subsets without active
epitope expression.47 VCAM-1 interactions are inhibited
completely by pretreatment of T cells with blocking anti-
bodies. Chigaev et al25 suggested that the unbending of
integrin, leading to conformational activation (as de-
tected by HUTS21), presumably exposes the VCAM-1
binding site.48 This possibility might account for an in-
crease in the tether frequency and correlate with cell attach-
ment to VCAM-1. Chigaev et al3 have also established that
the rate of HUTS21 binding is also related to the VLA-4
activation state, even at a saturating ligand concentration.
Conformational unbending of the integrin molecule could
facilitate both tethering and rolling.49 More important, the
specific inhibitor of Rac1, NSC, decreased expression of
conformationally active VLA-4 to the same extent as did the
GSK3 inhibitors (Figures 4 and 5).
Kiosses et al39 have demonstrated that Rac1 recruits
high-affinity integrins localized at the leading edge of
spreading and migrating cells. VLA-4 activation local-
izes to lamellipodia50 that are required for leukocyte
migration. Therefore, we evaluated the effects of LDV
stimulation on lamellipodia formation and cytoskeleton
alterations. Treatment with LDV resulted in a significant
increase in lamellipodia and redistribution of actin (Figure
8). GSK3 inhibitors diminished lamellipodia formation to
control levels in primary human monocytes and U937
cells (Figure 8, A–C). Stimulation of Rho GTPases re-
sulted in a similar lamellipodia increase, which was inhib-ited by a specific Rac1 inhibitor, indicating the involve-
ment of Rac1 in this process.
Because GSK3 inhibition in monocytes decreased
monocyte adhesion to and migration across BMVEC
monolayers, we investigated whether it could also protect
barrier function. Previously, we showed13 that BMVEC
engagement by monocytes resulted in diminished barrier
tightness (indicated by a TEER decrease) that was re-
versed by GSK3 suppression in BMVECs. The current
study demonstrated that suppression of GSK3 in U937
cells and in primary human monocytes attenuated barrier
dysfunction (Figure 3), paralleling decreased adhesion,
diminished expression of active VLA-4, and lamellipodia
formation. The notion that BBB impairment is associ-
ated with leukocyte migration into the central nervous
system is well accepted.51 Disengagement of inflam-
matory cells from brain endothelium via GKS3 inhibi-
tion may prove beneficial in multiple sclerosis, stroke,
and infection-driven encephalitis, among other inflam-
matory conditions.
Figure 9. Cellular signaling events halting the ability of monocytes to en-
gage brain microvascular endothelial cells and migrate across the BBB after
GSK3 inhibition. On interaction with ligand, integrins  and  change their
conformation from a nonactive (low-affinity) form to an active (high-affinity)
form and consequently mediate extracellular signals to cytoskeletal elements
and signaling factors via Rac1 GTPase proteins. Paxillin, talin, and vinculin
are cytoskeleton (actin)-interacting proteins that are involved in inside-out
integrin signaling. Inhibition of GSK3 affects inside-out and outside-in integrin
signaling via diminished Rac 1 GTPase activity, thereby affecting activation of
VASP and cofilin and actin rearrangements. As a result of these events, lamelli-
podia formation, adhesion, and migration of monocytes through the brain
endothelial monolayer are affected. PAK, p21-activated kinase.
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changes, depending on whether the cell is circulating
within the bloodstream or migrating through tissues. Cy-
toskeleton-inhibiting proteins, such as cofilin, regulate
rearrangements for these different cell states.52 Serine 3
phosphorylation of cofilin, an actin-depolymerizing pro-
tein, promotes the disassembly of F-actin, thereby ren-
dering cofilin unable to depolymerize F-actin and stabi-
lizing the cytoskeleton.53 Therefore, we investigated the
effect of GSK3 suppression on levels of phosphorylat-
ed/total cofilin in U937 cells and showed that GSK3
inhibition increased the amount of phosphorylated cofilin,
without a significant change in total cofilin (Figure 7). The
specific Rac1 inhibitor demonstrated the same changes.
VASP is involved in filopodia formation and regulation
of actin cytoskeleton formation. Human VASP harbors
three phosphorylation sites, including S157, S239, and
T278. The last two sites are associated with impaired
filament formation,38 whereas S157 is involved in binding
to focal adhesion proteins, such as paxillin, vinculin, and
talin.54 Dephosphorylation of VASP allows its binding to
talin, which, in turn, binds to integrin cytoplasmic do-
mains, leading to a separation of the integrin cytoplasmic
domains and inside-out activation.4 Our results indicate
that two of the three GSK3 inhibitors tested increased
phosphorylation of VASP at S157. VASP phosphorylation
of S157 has inhibited neutrophil migration and is associ-
ated with integrin 2 regulation.55 Additional studies are
necessary to prove whether GKS3 inhibition regulates
active conformation of integrin 1 via VASP phosphory-
lation. Figure 9 summarizes potential intracellular path-
ways associated with GSK3 inhibition in monocytes,
leading to the decreased ability to adhere/migrate and to
engage brain endothelium. These observations suggest
that GSK3 inhibition in leukocytes could be a target for
therapeutic intervention of neuroinflammatory disorders.
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